Reviews Fluticasone Propionate


No reviews yet.

Advair Diskus Drug Description
ADVAIR DISKUS 100/50
(fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 250/50
(fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 500/50
(fluticasone propionate 500 mcg and salmeterol 50 mcg inhalation powder)
FOR ORAL INHALATION

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol,
one of the active ingredients in ADVAIR DISKUS®, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual
asthma therapy showed an increase in asthma-related deaths in patients receiving
salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol
versus 3 deaths out of 13,179 patients on placebo). Currently available data
are inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of asthma-related
death from LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric and adolescent
patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR DISKUS) if possible
without loss of asthma control and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair Diskus »




ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are combinations
of fluticasone propionate and salmeterol xinafoate.
One active component of ADVAIR DISKUS is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3¬≠oxoandrosta-1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR DISKUS is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2­naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1¬≠[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 •C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially
designed plastic devices containing a double-foil blister strip of a powder
formulation of fluticasone propionate and salmeterol xinafoate intended for
oral inhalation only. Each blister on the double-foil strip within the device
contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg
of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base,
in 12.5 mg of formulation containing lactose (which contains milk proteins).
Each blister contains 1 complete dose of both medications. After a blister containing
medication is opened by activating the device, the medication is dispersed into
the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, ADVAIR DISKUS delivers
93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base
per blister from ADVAIR DISKUS 100/50, 250/50, and 500/50, respectively, when
tested at a flow rate of 60 L/min for 2 seconds. In adult patients with obstructive
lung disease and severely compromised lung function (mean FEV1 20%
to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS®
inhalation device was 82.4 L/min (range: 46.1 to 115.3 L/min).
Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult
(N = 17, aged 18 to 50 years) patients with asthma inhaling maximally through
the DISKUS device show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min).
Inhalation profiles for pediatric patients with asthma inhaling maximally through
the DISKUS device show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min)
for the 4-year-old patient set (N = 20) and 107.3 L/min (range: 82.8 to 125.6
L/min) for the 8-year-old patient set (N = 20).
The actual amount of drug delivered to the lung will depend on patient factors,
such as inspiratory flow profile.
Last reviewed on RxList: 7/22/2010




Advair Diskus Drug Description
ADVAIR DISKUS 100/50
(fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 250/50
(fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 500/50
(fluticasone propionate 500 mcg and salmeterol 50 mcg inhalation powder)
FOR ORAL INHALATION

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol,
one of the active ingredients in ADVAIR DISKUS®, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual
asthma therapy showed an increase in asthma-related deaths in patients receiving
salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol
versus 3 deaths out of 13,179 patients on placebo). Currently available data
are inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of asthma-related
death from LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric and adolescent
patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR DISKUS) if possible
without loss of asthma control and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair Diskus »




ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are combinations
of fluticasone propionate and salmeterol xinafoate.
One active component of ADVAIR DISKUS is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3¬≠oxoandrosta-1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR DISKUS is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2­naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1¬≠[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 •C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially
designed plastic devices containing a double-foil blister strip of a powder
formulation of fluticasone propionate and salmeterol xinafoate intended for
oral inhalation only. Each blister on the double-foil strip within the device
contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg
of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base,
in 12.5 mg of formulation containing lactose (which contains milk proteins).
Each blister contains 1 complete dose of both medications. After a blister containing
medication is opened by activating the device, the medication is dispersed into
the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, ADVAIR DISKUS delivers
93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base
per blister from ADVAIR DISKUS 100/50, 250/50, and 500/50, respectively, when
tested at a flow rate of 60 L/min for 2 seconds. In adult patients with obstructive
lung disease and severely compromised lung function (mean FEV1 20%
to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS®
inhalation device was 82.4 L/min (range: 46.1 to 115.3 L/min).
Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult
(N = 17, aged 18 to 50 years) patients with asthma inhaling maximally through
the DISKUS device show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min).
Inhalation profiles for pediatric patients with asthma inhaling maximally through
the DISKUS device show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min)
for the 4-year-old patient set (N = 20) and 107.3 L/min (range: 82.8 to 125.6
L/min) for the 8-year-old patient set (N = 20).
The actual amount of drug delivered to the lung will depend on patient factors,
such as inspiratory flow profile.
Last reviewed on RxList: 7/22/2010




Advair Diskus Drug Description
ADVAIR DISKUS 100/50
(fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 250/50
(fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 500/50
(fluticasone propionate 500 mcg and salmeterol 50 mcg inhalation powder)
FOR ORAL INHALATION

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol,
one of the active ingredients in ADVAIR DISKUS®, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual
asthma therapy showed an increase in asthma-related deaths in patients receiving
salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol
versus 3 deaths out of 13,179 patients on placebo). Currently available data
are inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of asthma-related
death from LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric and adolescent
patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR DISKUS) if possible
without loss of asthma control and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair Diskus »




ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are combinations
of fluticasone propionate and salmeterol xinafoate.
One active component of ADVAIR DISKUS is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3¬≠oxoandrosta-1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR DISKUS is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2­naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1¬≠[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 •C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially
designed plastic devices containing a double-foil blister strip of a powder
formulation of fluticasone propionate and salmeterol xinafoate intended for
oral inhalation only. Each blister on the double-foil strip within the device
contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg
of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base,
in 12.5 mg of formulation containing lactose (which contains milk proteins).
Each blister contains 1 complete dose of both medications. After a blister containing
medication is opened by activating the device, the medication is dispersed into
the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, ADVAIR DISKUS delivers
93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base
per blister from ADVAIR DISKUS 100/50, 250/50, and 500/50, respectively, when
tested at a flow rate of 60 L/min for 2 seconds. In adult patients with obstructive
lung disease and severely compromised lung function (mean FEV1 20%
to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS®
inhalation device was 82.4 L/min (range: 46.1 to 115.3 L/min).
Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult
(N = 17, aged 18 to 50 years) patients with asthma inhaling maximally through
the DISKUS device show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min).
Inhalation profiles for pediatric patients with asthma inhaling maximally through
the DISKUS device show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min)
for the 4-year-old patient set (N = 20) and 107.3 L/min (range: 82.8 to 125.6
L/min) for the 8-year-old patient set (N = 20).
The actual amount of drug delivered to the lung will depend on patient factors,
such as inspiratory flow profile.
Last reviewed on RxList: 7/22/2010




Advair Diskus Drug Description
ADVAIR DISKUS 100/50
(fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 250/50
(fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 500/50
(fluticasone propionate 500 mcg and salmeterol 50 mcg inhalation powder)
FOR ORAL INHALATION

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol,
one of the active ingredients in ADVAIR DISKUS®, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual
asthma therapy showed an increase in asthma-related deaths in patients receiving
salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol
versus 3 deaths out of 13,179 patients on placebo). Currently available data
are inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of asthma-related
death from LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric and adolescent
patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR DISKUS) if possible
without loss of asthma control and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair Diskus »




ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are combinations
of fluticasone propionate and salmeterol xinafoate.
One active component of ADVAIR DISKUS is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3¬≠oxoandrosta-1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR DISKUS is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2­naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1¬≠[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 •C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially
designed plastic devices containing a double-foil blister strip of a powder
formulation of fluticasone propionate and salmeterol xinafoate intended for
oral inhalation only. Each blister on the double-foil strip within the device
contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg
of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base,
in 12.5 mg of formulation containing lactose (which contains milk proteins).
Each blister contains 1 complete dose of both medications. After a blister containing
medication is opened by activating the device, the medication is dispersed into
the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, ADVAIR DISKUS delivers
93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base
per blister from ADVAIR DISKUS 100/50, 250/50, and 500/50, respectively, when
tested at a flow rate of 60 L/min for 2 seconds. In adult patients with obstructive
lung disease and severely compromised lung function (mean FEV1 20%
to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS®
inhalation device was 82.4 L/min (range: 46.1 to 115.3 L/min).
Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult
(N = 17, aged 18 to 50 years) patients with asthma inhaling maximally through
the DISKUS device show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min).
Inhalation profiles for pediatric patients with asthma inhaling maximally through
the DISKUS device show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min)
for the 4-year-old patient set (N = 20) and 107.3 L/min (range: 82.8 to 125.6
L/min) for the 8-year-old patient set (N = 20).
The actual amount of drug delivered to the lung will depend on patient factors,
such as inspiratory flow profile.
Last reviewed on RxList: 7/22/2010




Advair Diskus Drug Description
ADVAIR DISKUS 100/50
(fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 250/50
(fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
ADVAIR DISKUS 500/50
(fluticasone propionate 500 mcg and salmeterol 50 mcg inhalation powder)
FOR ORAL INHALATION

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists (LABA), such as salmeterol,
one of the active ingredients in ADVAIR DISKUS®, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual
asthma therapy showed an increase in asthma-related deaths in patients receiving
salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol
versus 3 deaths out of 13,179 patients on placebo). Currently available data
are inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of asthma-related
death from LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric and adolescent
patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR DISKUS) if possible
without loss of asthma control and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair Diskus »




ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are combinations
of fluticasone propionate and salmeterol xinafoate.
One active component of ADVAIR DISKUS is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3¬≠oxoandrosta-1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR DISKUS is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2­naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1¬≠[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 •C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially
designed plastic devices containing a double-foil blister strip of a powder
formulation of fluticasone propionate and salmeterol xinafoate intended for
oral inhalation only. Each blister on the double-foil strip within the device
contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg
of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base,
in 12.5 mg of formulation containing lactose (which contains milk proteins).
Each blister contains 1 complete dose of both medications. After a blister containing
medication is opened by activating the device, the medication is dispersed into
the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, ADVAIR DISKUS delivers
93, 233, and 465 mcg of fluticasone propionate and 45 mcg of salmeterol base
per blister from ADVAIR DISKUS 100/50, 250/50, and 500/50, respectively, when
tested at a flow rate of 60 L/min for 2 seconds. In adult patients with obstructive
lung disease and severely compromised lung function (mean FEV1 20%
to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS®
inhalation device was 82.4 L/min (range: 46.1 to 115.3 L/min).
Inhalation profiles for adolescent (N = 13, aged 12 to 17 years) and adult
(N = 17, aged 18 to 50 years) patients with asthma inhaling maximally through
the DISKUS device show mean PIF of 122.2 L/min (range: 81.6 to 152.1 L/min).
Inhalation profiles for pediatric patients with asthma inhaling maximally through
the DISKUS device show a mean PIF of 75.5 L/min (range: 49.0 to 104.8 L/min)
for the 4-year-old patient set (N = 20) and 107.3 L/min (range: 82.8 to 125.6
L/min) for the 8-year-old patient set (N = 20).
The actual amount of drug delivered to the lung will depend on patient factors,
such as inspiratory flow profile.
Last reviewed on RxList: 7/22/2010





Other reviews about Fluticasone Propionate on wordpress

FDA Approves First Generic Version Of Flonase
  by rognar
The Food and Drug Administration (FDA) today approved Fluticasone Propionate Nasal Spray, the first generic version of the brand name drug Flonase, giving American consumers an additional, lower […]


Fluticasone propionate reduces bacterial airway epithelial invasion
  by JOC
European Respiratory Journal¬† 1 November 2008¬† V.32¬† N.5¬† p.1283-1288 M. Barbier1, A. Agust√≠2,3,4 and S. Albert√≠1 1 University Institute of Health Sciences Research (IUNICS), University of the Balearic Islands, […]


Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate
  by JOC
The American Journal of Gastroenterology Mar 2004 V.98 N.10 p.2146-2148 Naoki Kanda, M.D. a , Hirotaka Yasuba, M.D., Ph.D. b , Teruko Takahashi, M.D. c , Yuka Mizuhara, […]


Nasal spray--free
  by webandnet
¬† https://www.veramyst.com/optin/savings.jsp ¬† This is same as fluticasone propionate (sp), which is only $25.¬† With doctor‚Äôs prescription Veramyst will give you a free 30 days supply.¬† ¬† ¬† Good time for nasal irrigation: ¬† Nasal […]


Researchers test drug combination to treat nasal, ocular allergy symptoms
  by eyeinfo
MedPage Today (11/11, Smith) reported that, according to a study published in the Annals of Allergy, Asthma, and Immunology and presented at an allergy conference, "the combination of […]


dance of the sugarloaf fairy
  by firthefirst
the moving-in saga continues, and has pretty much consumed all of my (and tina's) post-work time this week.¬† that, and driving to the wrong airport to pick up […]


Flonase - Nasal Spray - Allergy Medicine
  by rathindey
Flonase is a nasal spray used in the treatment of sneezing congestion itching and runniness in the nose. Flonase is an anti-inflammatory containing Fluticasone […]


Asthma Rotahaler
  by rathindey
Rotahaler [Fluticasone propionate + Salmeterol] is a potent synthetic anti-inflammatory medication used in the treatment of Bronchospasm and chronic obstructive lung disease. It is […]


FDA MedWatch - June 2010 Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch June 2010 Drug Safety Labeling Changes posting includes 28 products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT […]


FDA MedWatch - Advair Diskus (fluticasone propionate and salmeterol inhalation powder): Stolen Product Warning
  by irbtipoftheweek
ISSUE: Certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be […]



Other reviews about Fluticasone Propionate on web:

Learn about the prescription medication Flonase (Fluticasone Propionate Nasal Spray), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Flonase (Fluticasone Propionate Nasal Spray) Drug Information ...


Fluticasone propionate is a synthetic corticosteroid derived from fluticasone used to treat asthma and allergic rhinitis (hay fever). It is also used to treat eosinophilic ... Fluticasone propionate - Wikipedia, the free encyclopedia


Learn about the nasal spray drug fluticasone (Flonase, Veramyst) used to treat non-allergic and allergic rhinitis and its symptoms like a stuffy and runny nose. fluticasone (Flonase, Veramyst) Drug Information on MedicineNet.com


Fluticasone is a synthetic glucocorticoid. Both the furoate and propionate forms are used as topical anti-inflammatories: Fluticasone propionate; Fluticasone furoate Fluticasone - Wikipedia, the free encyclopedia


Learn about the prescription medication Flovent (Fluticasone Propionate), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Flovent (Fluticasone Propionate) Drug Information: Uses, Side ...


Comprehensive and trusted information about Fluticasone propionate - plus advice on 24,000 other FDA approved drugs and medications from Drugs.com. Fluticasone propionate patient advice including side effects


Medical information about asthma symptoms and relief therapies: doctor produced and written for patients experiencing asthma related conditions to make informed health decisions. fluticasone propionate oral inhaler - Asthma Symptoms, Relief ...


Fluticasone Propionate is a corticosteroid used to reduce itching, redness, and swelling associated with many skin conditions. Side effects and interactions are available at ... Fluticasone Propionate - drugstore.com. Low prices, side effects ...


Resource URI: http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00588 Fluticasone Propionate | D2R Server publishing the DrugBank ...


Fluticasone Propionate Topical cream To return to the main entry click here . What is this medicine? FLUTICASONE (floo TIK a sone) is a corticosteroid Fluticasone Propionate Topical cream: Information from Answers.com





Featured Reviews

Reviews Everolimus

Zortress Drug Description Zortress (everolimus) WARNING WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS Increased susceptibility to infection and the possible development of malignancies such as lymphoma and skin...
Read More  |  Review This
Reviews Treximet

Treximet Drug Description TREXIMET® (sumatriptan and naproxen sodium) Tablets WARNINGS Cardiovascular Risk: TREXIMET may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which...
Read More  |  Review This
Reviews Melphalan Hcl Injection

Alkeran Injection Drug Description ALKERAN® (melphalan hydrochloride) for Injection WARNING Melphalan should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents....
Read More  |  Review This
Reviews Vaseretic

Vaseretic Drug Description VASERETIC® (enalapril maleate-hydrochlorothiazide) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing...
Read More  |  Review This
Reviews Cystagon

Cystagon Drug Description CYSTAGON® (cysteamine bitartrate capsules) 50 mg and 150 mg DRUG DESCRIPTION What are the possible side effects of cysteamine (Cystagon)? Get emergency medical help if your child has any of these signs...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....